MYOMO, INC.(MYO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,502 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
MYO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for MYOMO, INC. (MYO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MYO at 30.2/100 on a 32-signal composite quality model, placing it at rank #2,502 of 2,962 stocks — the bottom half of the AI-ranked universe. MYO scores in the top quartile across revenue growth (91.2). Areas of concern include balance sheet strength (5.3) and revenue scale (7.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MYOMO, INC. reports quarterly revenue of $11.7M, net income of $-4.0M, free cash flow of $-2.0M. Top institutional holders of MYO by reported 13-F value include Rosalind Advisors, VANGUARD CAPITAL MANAGEMENT, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. MYO trades on the NYSE exchange and files with the SEC under CIK 1369290. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MYO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MYOMO, INC. directly from SEC EDGAR. MYOMO, INC.'s 13F Pro composite quality score has ranged between 28 and 32 since 2025, currently 30.2 — a stable long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q2 2026
$11.7M
Net Income
Q2 2026
$-4.0M
Free Cash Flow
Q2 2026
$-2.0M
ROIC
Q2 2026
-50.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+25.7% YoYNet Income
-151.9% YoYOperating Income
-132.0% YoYEPS (Diluted)
-131.3% YoYTotal Assets
-8.5% YoYTotal Debt
-20.8% YoYOp. Cash Flow
-341.1% YoYFree Cash Flow
-249.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $40.9M +25.7% | $32.6M +69.2% | $19.2M +23.7% | $15.6M +12.3% | $13.9M +82.7% | $7.6M |
| Net Income | $-15.6M -151.9% | $-6.2M +24.1% | $-8.1M +24.0% | $-10.7M -3.4% | $-10.4M +10.3% | $-11.6M |
| Operating Income | $-14.4M -132.0% | $-6.2M +24.6% | $-8.2M +22.9% | $-10.7M -3.9% | $-10.3M +2.2% | $-10.5M |
| EPS (Diluted) | $-0.37 -131.3% | $-0.16 +42.9% | $-0.28 +81.6% | $-1.52 +19.6% | $-1.89 | — |
| Total Assets | $38.6M -8.5% | $42.2M +189.7% | $14.6M +43.5% | $10.2M -49.4% | $20.1M +36.6% | $14.7M |
| Total Debt | $11.2M -20.8% | $14.2M | — | — | — | — |
| Operating Cash Flow | $-14.5M -341.1% | $-3.3M +46.7% | $-6.2M +39.7% | $-10.2M -7.2% | $-9.5M -5.7% | $-9.0M |
| Free Cash Flow | $-16.3M -249.5% | $-4.7M +26.4% | $-6.3M +38.9% | $-10.3M -4.8% | $-9.9M -8.8% | $-9.1M |
Get alerted when MYO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MYOMO, INC. including:
Top Institutional Holders of MYO
Rosalind Advisors, Inc.
$3.8M3,637,886 shVANGUARD CAPITAL MANAGEMENT LLC
$1.7M1,636,570 shAQR CAPITAL MANAGEMENT LLC
$965.4K928,268 shLEUCADIA NATIONAL CORP
$732.4K704,275 shJANE STREET GROUP, LLC
$620.2K596,352 shClearstead Advisors, LLC
$442.6K425,609 shUBS Group AG
$430.2K413,679 shGEODE CAPITAL MANAGEMENT, LLC
$358.3K344,417 shLPL Financial LLC
$320.3K308,000 shPalumbo Wealth Management LLC
$311.8K299,776 sh
| Fund | Value | Shares |
|---|---|---|
| Rosalind Advisors, Inc. | $3.8M | 3,637,886 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.7M | 1,636,570 |
| AQR CAPITAL MANAGEMENT LLC | $965.4K | 928,268 |
| LEUCADIA NATIONAL CORP | $732.4K | 704,275 |
| JANE STREET GROUP, LLC | $620.2K | 596,352 |
| Clearstead Advisors, LLC | $442.6K | 425,609 |
| UBS Group AG | $430.2K | 413,679 |
| GEODE CAPITAL MANAGEMENT, LLC | $358.3K | 344,417 |
| LPL Financial LLC | $320.3K | 308,000 |
| Palumbo Wealth Management LLC | $311.8K | 299,776 |
Companies Similar to MYO
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
FENNEC PHARMACEUTICALS INC.
X4 Pharmaceuticals, Inc
Ovid Therapeutics Inc.
CG Oncology, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put MYO on your watchlist
Track score changes the day MYOMO, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MYO a good stock to buy?
13F Pro's AI-powered analysis of MYOMO, INC. (MYO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MYO are available on the MYO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MYO is classified as a small company.
Which hedge funds own MYO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MYO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MYOMO, INC.'s investment landscape.